Dapagliflozin combined with sitagliptin in treatment of type 2 diabetes
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 3
Abstract
Objective To investigate the efficacy of single drug treatment of dapagliflozin and combination of dapagliflozin and sitagliptin in the treatment of type 2 diabetes mellitus (T2DM). Methods Sixty-two patients with T2DM admitted to Luhe District Hospital of Chinese Medicine from January 2022 to December 2023 were selected as research subjects, and the patients were randomly divided into two groups, with 31 cases in each group. The control group only received treatment with dapagliflozin (10 mg/d oral), while the observation group received both dapagliflozin (10 mg/d oral) and sitagliptin (100 mg/d oral) treatment. Both groups were treated for 3 months. The post-treatment blood glucose control effects ［fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c)］, blood glucose fluctuations, inflammatory markers ［C-reactive protein (CRP)］, and cardiac function ［left ventricular ejection fraction (LVEF)］ were compared between two groups. Results After 3 months of treatment, compared with before treatment, both groups showed a significant decrease in FPG and HbA1c after treatment (P＜0.05). Compared with the control group, FPG ［(6.96±0.87) mmol/L vs (7.91±0.96) mmol/L, t=4.083, P＜0.01］ and HbA1c ［(6.54±0.33)% vs (7.65±0.58)%, t=9.261, P＜0.01］ of patients in the observation group were significantly decreased, and the standard deviation of mean blood glucose (SDBG) and amplitude of postprandial blood glucose fluctuation (PPGE) were lower (P<0.05), CRP was lower and LVEF was higher (P<0.05) in the observation group compared to the control group. Conclusion Dapagliflozin combined with sitagliptin has a significant effect in the treatment of T2DM. It can effectively reduce the level of blood glucose, reduce the occurrence of hypoglycemia, and improve the inflammatory reaction and cardiac function of patients.
Authors and Affiliations
CHEN Hui, LIN Yuesong, PEI Qin, ZHAO Lingang
Keywords
Related Articles
- EP ID EP734511
- DOI 10.13429/j.cnki.cjcr.2024.03.016
- Views 10
- Downloads 0
Progress on the impact of lipid metabolism reprogramming on resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer
Non-small cell lung cancer (NSCLC) is the main type of lung cancer, accounting for 85% to 90% of cases. The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has greatly improved the prognosi...
Claudin18.2： an emerging target for the treatment of gastric cancer
Gastric cancer is a malignant tumor that seriously endangers human health. Claudin18.2 (CLDN18.2) is a transmembrane protein and a main component of tight junctions that plays an important role in maintaining barrier fun...
Research progress on the pathogenesis and treatment of cervical spondylotic myelopathy
Cervical spondylotic myelopathy (CSM) is the most serious subtype of cervical spondylosis, which is the main cause of spinal cord dysfunction in middle-aged and elderly people, and the pathogenesis of this CSM is complex...
Circulating tumor cell with neutrophil to lymphocyte ratio in predicting efficacy of advanced gastric cancer
<b>Objective</b> To investigate the predictive effect of circulating tumor cell (CTC) combined with neutrophil to lymphocyte ratio (NLR) on efficacy of advanced gastric cancer. <b>Methods</b> The clinicopathological data...
Artificial intelligence advancements in breast cancer ultrasound screening
Ultrasound is the first-line screening method for breast cancer. The application of BI-RADS makes the ultrasound diagnosis of breast diseases relatively consistent, but it is still affected by subjective factors of opera...